Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.
Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.
The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.
In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.
Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.
Cerus Corporation (CERS) reported a strong first-quarter 2022 performance with total revenue of $43.0 million, reflecting a 46% year-over-year increase. Product revenue reached $37.4 million, up 60% year-over-year. The company improved its 2022 product revenue guidance to a range of $160-165 million, a 22%-26% increase over 2021. Net loss decreased to $12.3 million from $17.5 million the previous year. Notable contracts include a multi-year agreement with the American Red Cross for INTERCEPT Platelet kits, reinforcing strong demand in the U.S.
Cerus Corporation has secured a ten-year deal with Fresenius Kabi to produce INTERCEPT Blood System sets, replacing the current contract that expires in July 2025. This collaboration aims to meet increasing global demand and enhance supply chain reliability. Manufacturing will expand to new facilities in the Caribbean and continue in France, ensuring redundancy and higher production volumes. This partnership is expected to deliver significant benefits for customers and shareholders, reinforcing Cerus' commitment to pathogen reduction in transfusion medicine.
Cerus Corporation has secured a five-year agreement with the American Red Cross to supply the INTERCEPT Blood System for Platelets. This contract aims to enhance patient access to pathogen-reduced platelets, reinforcing the Red Cross's commitment to blood safety. As the largest blood provider in the U.S., collecting over 4.6 million donations in 2021, the Red Cross will continue using Cerus' technology to meet FDA safety standards. This partnership is expected to ensure the availability of safe blood transfusions for hospitals, physicians, and patients nationwide.
Cerus Corporation (CERS) will release its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will occur at 4:30 P.M. ET to discuss the results and provide a business overview. The INTERCEPT Blood System, crucial for pathogen protection in blood components, is marketed globally, with the red blood cell system under regulatory review in Europe. The company aims to enhance blood safety and solidify its position as a global leader.
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. EST. A live webcast will be accessible on the company's Investor Relations page, with a replay available for two weeks post-event. Cerus focuses on ensuring the safety of the global blood supply with products like the INTERCEPT Blood System, which is FDA-approved for platelets and plasma and under review for red blood cells in Europe. More details can be found on their website.
Cerus Corporation (CERS) reported a robust Q4 2021 with total revenues of $50.1 million, up 49% year-over-year, driven by a 41% increase in product revenues to $39.9 million. The full-year revenue reached $159.5 million, a 40% increase from 2020. The company reiterated its 2022 product revenue guidance of $157-$164 million, indicating expected growth of 20%-25%. Notably, government contract revenues surged by 90% to $10.2 million in Q4. However, net loss narrowed to $9.1 million, down from $14.4 million in Q4 2020.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market close. A conference call will follow at 4:30 P.M. ET, providing insights into the company’s performance and future outlook. Investors can access the live webcast on Cerus’ Investor Relations page or by calling U.S. (866) 235-9006 or international (631) 291-4549.
Additionally, a replay will be available post-call through March 8, 2022.
Cerus Corporation (CERS) announced its participation in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference. Vivek Jayaraman, COO, will present on February 16 at 9:00 a.m. EST, while CFO Kevin Green will participate on February 18 at 12:00 p.m. EST. The events are for BTIG clients, and webcasts can be accessed via Cerus' investor relations webpage. Cerus focuses on safeguarding the blood supply globally, offering the INTERCEPT Blood System, which has CE and FDA approvals for pathogen reduction.
Cerus Corporation (CERS) announced preliminary product revenues for Q4 2021 at
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Stephens Annual Investment Conference on December 3, 2021, at 2:00 p.m. ET in Nashville, Tennessee. A live webcast will be accessible on the Cerus Investor Relations page, with a replay available for about two weeks post-event. Cerus is focused on safeguarding the global blood supply, offering technologies like the INTERCEPT Blood System, which has CE Mark and FDA approval for pathogen reduction in platelets and plasma. For details, visit www.cerus.com/ir.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
